Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Breast 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 299Solid Tumors 184Advanced Solid Tumors 168Solid Tumor 152Mesothelioma, Malignant 152Mesothelioma 121Advanced Solid Tumor 97Carcinoma, Non-Small-Cell Lung 50Retinoblastoma 48Lung Neoplasms 37Solid Tumor, Adult 36Sarcoma 31Ovarian Neoplasms 29Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Small Cell Lung Carcinoma 25Melanoma 25Pancreatic Neoplasms 24Breast Neoplasms 24Unspecified Childhood Solid Tumor, Protocol Specific 23Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Solid Tumours 20Solitary Fibrous Tumor, Pleural 19Osteosarcoma 19Colorectal Neoplasms 17Neuroblastoma 16Head and Neck Neoplasms 16Carcinoma, Hepatocellular 16

Interventions

trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors (Excluding Breast Cancer) × Other solid neoplasm × Clear all
NCT01867879 2024-09-05

Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors

Taiho Oncology, Inc.

Phase 1 Completed
44 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

NCT01874522 2024-09-05

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Taiho Oncology, Inc.

Phase 1 Completed
46 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors (Excluding Breast Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡